

At Eisai, our corporate mission is to create and increase patient value, specifically through (1) satisfying unmet medical needs, (2) ensuring a stable supply of high-quality products and (3) providing



## Priority Projects Progress Report


### Microtubule Dynamics Inhibitor E7389 (Breast cancer, non-small cell lung cancer, prostate cancer, sarcoma)

Clinical trials for the indication of breast cancer have advanced to Phase III in Europe and the United States, and to Phase II in Japan. Simultaneous application for this indication in Japan, the United States and Europe is planned for the fiscal year ending March 31, 2010. Clinical trials for the indication of non-small cell lung cancer have entered Phase II in the United States, as have trials for the indication of prostate cancer in the United States and Europe and trials for the indication of sarcoma in Europe.



### Endotoxin Antagonist E5564 (Severe sepsis)

International Phase III trials are under way.



## Enhanced Presence in Oncology

Eisai has proactively sought to strengthen its R&D and commercial structure related to oncology, through its acquisition of four oncology products from U.S.-based Ligand Pharmaceuticals Inc. in October 2006, and its April 2007 acquisition of U.S.-based biotechnology firm Morphotek, Inc. In January 2008, Eisai gained an immediate and full-fledged presence in the oncology field with its acquisition of MGI PHARMA, INC. Leveraging MGI's products and product candidates and utilizing its own global development strengths and marketing network, Eisai aims to tap the unlimited potential of oncology.